Gastroesophageal Reflux Disease (GERD) Devices Market: Boost in Adoption Expected in Clinics & Diagnostic Centers
Exceeding the revenue of US$ 1.17 billion in 2022, the global sales of gastroesophageal disease devices will witness a steady over 4.3% CAGR during 2022-2028. As indicated in a new intelligence outlook of Future Market Insights (FMI), esphagoscopes and gastroscopes will continue to account for most of the sales. Adoption of gastroesophageal reflux disease devices will remain maximum for diagnostic procedures, followed by fundoplication procedures.
More Patients Continue to Prefer GERD Devices over Lifestyle Modifications & PPIs
Besides the rapid expansion of geriatric population and elevating prevalence rate of obesity-driven gastroeasophageal reflux diseases, FMI in a new study states that the frequent intake of asthma medications is also a strong impact factor associated with the growth of gastroesophageal reflux disease devices market.
Although industry experts recommend lifestyle modifications as the most suitable remedy for gastroesophageal diseases, the growing demand for surgeries for obesity will continue to drive sales of gastroesophageal disease devices in coming years.
Request a report sample to gain comprehensive insights at https://www.futuremarketinsights.com/reports/sample/REP-GB-1741
The second line of treatment for gastroesophageal reflux disease includes proton pump inhibitors (PPI) therapy, which can reduce the usage of gastroesophageal reflux disease devices. Proton pump inhibitors are the drugs that regulate acid production within stomach, and thereby restrict gastroesophageal reflux.
However, the proven side effects and functional failure of proton pump inhibitors in the long run will continue to benefit the demand for surgical treatment of gastroesophageal reflux disease, favoring the overall sales of gastroesophageal reflux disease devices such as PH monitoring system and manometry system.
Diagnostic Centers & Private Clinics to Employ More GERD Devices
While a majority of adoption of gastroesophageal reflux disease devices prevails in hospitals, the constantly increasing number of establishments in the ambulatory surgical center and diagnostic center segments is likely to translate into a higher rate of adoption of gastroesophageal reflux disease devices within the latter two.
With the number of diagnostic centers and private practice clinics on the constant rise, it is more likely that the demand for gastroesophageal reflux disease devices will observe steady growth over the years to come. Towards the end of forecast period, global market value share of clinics and diagnostic centers will be more than 35%, as suggested by FMI’s analysis of the gastroesophageal reflux disease devices market.
For any Queries Related with the Report, Ask an Analyst@ https://www.futuremarketinsights.com/ask-question/rep-gb-1741
Key GERD Device Manufacturers Eyeing New Product Launches
The report tracks some of the key companies operating in the Gastroesophageal Reflux Disease Devices market, such as Olympus Corporation, Pentax Medical, Medtronic Plc., Diversatek Inc. The report also tracks the key manufacturers operating in gastroesophageal reflux disease treatment devices, such as EndoGastric Solutions, Medigus Ltd., Torax Medical, Inc. and Mederi RF, Inc.
A majority of key manufacturers of gastroesophageal reflux disease devices are emphasizing new product launches. Innovation of new and advanced products is in turn shaping the growth of gastroesophageal reflux disease devices market.
According to the report findings,
- Olympus Corporation and Pentax Medical hold the maximum company share in the gastroesophageal reflux disease devices market.
- Olympus Corporation recently launched an advanced version of esophagoscope and gastroscope.
- Plc. and Diversatek, Inc. are the key players of diagnostic devices for gastroesophageal reflux disease, contributing a significant share in overall gastroesophageal reflux disease devices market.
- EsophyX Z is the new and advanced version of EsophyX gastroesophageal reflux disease device, used for the transoral incisionless fundoplication process.
We Offer tailor-made Solutions to fit Your Requirements, Request Customization @ https://www.futuremarketinsights.com/customization-available/rep-gb-1741
Explore FMI’s Extensive ongoing Coverage on Healthcare Domain
Autoimmune Disease Therapeutics Market – Autoimmune diseases is a body’s hyperactive immune response against the substances and tissues normally present in the body. Autoimmune diseases are more commonly caused by genetic, infectious or environmental factors.
Infectious Disease Diagnostics Market – Infectious disease diagnostics is process of identifying the presence of foreign antigen/organism with the help of various diagnostic tools. Infectious disease conditions are highly prevalent in under developed regions due to lack of awareness for personal hygiene, minimal healthcare expenditures and absence of efficient physician services.
Neurodegenerative Disease Market – The neurodegenerative disease market is anticipated to register a CAGR of 7% during the forecast period, up from US$ 43.7 Bn in 2021 to reach a valuation of US$ 92 Bn by 2032.
About Future Market Insights (FMI)
Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in Dubai, and has delivery centers in the UK, U.S. and India. FMI’s latest market research reports and industry analysis help businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.
Future Market Insights,
1602-6 Jumeirah Bay X2 Tower,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
For Sales Enquiries: email@example.com